Chemotherapy Before Surgery Improves Survival in Pancreatic Cancer with Vein Involvement

Recent research suggests that administering chemotherapy before surgery significantly improves survival rates for patients with upfront resectable pancreatic ductal adenocarcinoma, particularly those with involvement of the portomesenteric vein (PMV). The findings challenge current NCCN guidelines, which classify tumors with limited vein involvement as immediately operable and suggest a shift in treatment sequencing may be warranted.

Understanding the Study Findings

A retrospective analysis of 1446 patients who underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma between 2002 and 2023 at three Mayo Clinic sites revealed key insights. The study, published in the Journal of the National Comprehensive Cancer Network, focused on patients with tumors abutting the portomesenteric vein.

Survival Rates with Upfront Surgery

Among patients who underwent surgery first, PMV abutment was a significant predictor of poorer outcomes. Patients with vein involvement had a median overall survival (OS) of 19.2 months, compared to 27.6 months for those without vein involvement (P < .05). The rate of complete tumor removal (R0 resection) was significantly lower in the group with vein abutment – 63.1% versus 87.2% without abutment (P < .05).

The Benefit of Neoadjuvant Therapy

Still, the administration of chemotherapy before surgery (neoadjuvant therapy) dramatically altered these outcomes. Patients with PMV abutment who received preoperative chemotherapy achieved a median OS of 42.5 months, while those without abutment reached 51.6 months (P = .48). More pronounced benefits were observed in patients treated since 2017, with modern chemotherapy regimens. In this group, patients without PMV abutment had a median OS of 45 months, compared to 20.4 months in those with PMV abutment who underwent upfront surgery (P < .05).

The R0 resection rate also improved significantly with neoadjuvant therapy, reaching 91.4% for those with vein abutment and 94.0% for those without.

Implications for Treatment Guidelines

The current NCCN guidelines classify tumors with 180 degrees or less of PMV abutment as “upfront resectable.” This study suggests that even minor vein involvement may warrant a shift towards neoadjuvant therapy to optimize patient outcomes.

“Many patients with early-stage pancreatic cancer undergo surgery first because it is historically believed to be the best chance for cure,” explained Zhi Ven Fong, MD, MPH, DrPH, a surgical oncologist at Mayo Clinic in Arizona and co-senior author of the study in a press release. “Our findings suggest that chemotherapy first, even in cases thought to be more straightforward, provides patients with the best opportunity for long-term survival.”

Study Details

The study retrospectively analyzed data from patients who underwent pancreatoduodenectomy for nonmetastatic, upfront resectable pancreatic ductal adenocarcinoma, as defined by NCCN criteria (no more than 180° PMV abutment without contour irregularity). Patients with arterial involvement were excluded. Neoadjuvant regimens typically included multi-agent chemotherapy, such as gemcitabine plus nab-paclitaxel. The primary endpoint was overall survival, with R0 resection rates and pathologic tumor characteristics as secondary endpoints.

Researchers also found that neoadjuvant therapy was associated with a reduction in pathologic tumor size. While some patients with PMV abutment required PMV resection, the study indicated that the biological response to chemotherapy, rather than the surgical approach, was the primary driver of improved outcomes.

Empowering Patients and Clinicians

Mark Truty, MD, a surgical oncologist at Mayo Clinic in Minnesota and co-senior author, emphasized the importance of informed decision-making. “Our hope is that this study empowers both patients and clinicians to think carefully about treatment sequencing. We desire people to know they have options, and that starting with chemotherapy may be the best path forward,” he stated in a press release.

Key Takeaways

• Neoadjuvant chemotherapy improves survival rates in patients with upfront resectable pancreatic ductal adenocarcinoma, especially those with portomesenteric vein involvement.
• Current NCCN guidelines may lead to suboptimal treatment sequencing for patients with even minor vein abutment.
• The biological response to chemotherapy is a key driver of improved outcomes, rather than aggressive surgical approaches.
• Patients should discuss the benefits of neoadjuvant therapy with their healthcare team.

Reference: Tan PH, Thiels CA, Poruk K, et al. Redefining upfront resectable pancreatic ductal adenocarcinoma: should vein abutment matter? J Natl Compr Canc Netw. 2026;24(2):27-33. Doi:10.6004/jnccn.2025.7097